Recruiting × Interventional × Biliary Tract Neoplasms × Clear all Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
Phase 2 Recruiting
294 enrolled
DESTINY-BTC01
Phase 3 Recruiting
620 enrolled
HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours
Phase 1/2 Recruiting
124 enrolled
ANTARES
Phase 2 Recruiting
28 enrolled
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
Phase 1 Recruiting
160 enrolled
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Phase 1 Recruiting
145 enrolled
Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer
Phase 2 Recruiting
40 enrolled
Beacon-BTC
Phase 3 Recruiting
480 enrolled
A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
Phase 1/2 Recruiting
102 enrolled
panSOHO
Phase 2 Recruiting
111 enrolled
HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer
Phase NA Recruiting
40 enrolled
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
Phase 1/2 Recruiting
342 enrolled
Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer
Phase 1 Recruiting
48 enrolled
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Phase 2 Recruiting
60 enrolled
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Phase 1 Recruiting
100 enrolled
SHIELD
Phase 2 Recruiting
20 enrolled
A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer
Phase 2 Recruiting
151 enrolled
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
Phase 1/2 Recruiting
60 enrolled
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Phase 3 Recruiting
286 enrolled
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Phase 1 Recruiting
280 enrolled
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Phase 2 Recruiting
454 enrolled
Study for AZD4360 in Participants With Advanced Solid Tumours
Phase 1/2 Recruiting
117 enrolled
AB02
Phase 3 Recruiting
1,100 enrolled
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
330 enrolled
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer
Phase 1/2 Recruiting
135 enrolled
Ligufalimab and Cadonilimab in Advanced Liver Cancers
Phase 2 Recruiting
64 enrolled
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
Phase 1/2 Recruiting
147 enrolled
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Phase NA Recruiting
360 enrolled
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Phase 2 Recruiting
27 enrolled
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
Phase 1 Recruiting
60 enrolled
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
Phase 1 Recruiting
171 enrolled
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
Phase 2 Recruiting
224 enrolled
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
Phase 2 Recruiting
520 enrolled
DVDMS
Phase 2 Recruiting
30 enrolled
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
Phase 1/2 Recruiting
796 enrolled
MK-9999-02A
Phase 1/2 Recruiting
220 enrolled
CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
Phase 1/2 Recruiting
50 enrolled
BRAVE
Phase NA Recruiting
120 enrolled
Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
Phase 1 Recruiting
20 enrolled
LNCB74-01
Phase 1 Recruiting
145 enrolled
An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.
Phase 2 Recruiting
300 enrolled
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Phase 1/2 Recruiting
27 enrolled
Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer
Phase 1 Recruiting
15 enrolled
Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)
Phase 1 Recruiting
25 enrolled
Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer
Phase 2 Recruiting
45 enrolled
Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
Phase 2 Recruiting
27 enrolled
SEVILLA
Phase 2 Recruiting
72 enrolled
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Phase 1/2 Recruiting
258 enrolled
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Phase 1/2 Recruiting
540 enrolled
LapTAP
Phase NA Recruiting
48 enrolled